Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) was the target of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 56,700 shares, a decrease of 28.8% from the May 15th total of 79,600 shares. Based on an average trading volume of 98,600 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.8% of the company’s stock are sold short.
Virpax Pharmaceuticals Stock Performance
Virpax Pharmaceuticals stock opened at $0.69 on Friday. Virpax Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $11.77. The firm’s fifty day simple moving average is $1.96 and its 200-day simple moving average is $3.01.
Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($2.75) earnings per share for the quarter.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on VRPX
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Recommended Stories
- Five stocks we like better than Virpax Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 6/10 – 6/14
- Insider Buying Explained: What Investors Need to Know
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.